Telix Joins Thera4Care to Advance Cancer Theranostics in Europe
By United One News · AI-generated summary of 2 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
Telix Pharmaceuticals joined the European research initiative Thera4Care to evaluate its FAP-targeting therapy candidate for metastatic solid tumors using terbium-161.
- The initiative brings together 27 partners from academic centers, healthcare providers, and industry groups across Europe.
- A Phase 1 clinical trial will explore the safety and activity of the terbium-161 labeled therapy.
- The study will initially focus on ovarian and pancreatic cancers as well as sarcomas.
“Telix is excited to join Thera4Care, a collaboration of leading academic and industry partners focused on advancing theranostics research.”
Covered by 2 outlets across the spectrum: 0% left, 100% center, 0% right.
How each side framed it
Boehringer Ingelheim and Sino Biopharmaceutical ink partnership to advance next─generation cancer therapies
Timeline
First to report: Pharmabiz (); 2 articles from 2 outlets so far.
Who is covering this story
- Center (2): Pharmabiz, PR Newswire Asia